VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary ...

VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary ...

GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.

Cell and gene therapies offer potential new therapeutics but are currently constrained by complex and inefficient manufacturing strategies.

Even after the pandemic, various new infectious diseases continue to emerge, posing ongoing viral threats that demand robust ...

May 2025 - eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic ...

ReiThera, the Italian CDMO company specialized in the development and manufacturing of genetic vaccines and advanced therapies, is pleased to announce its participation in the 27th Annual Meeting of ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

Researchers have identified a never-before-seen mechanism that enables HIV-1 to evade the body's natural defenses and use it to support its survival and replication. The 'loophole' is a biological ...

Xmoor Pharma has entered into a strategic partnership with KU Leuven to support a new cell and gene therapy hub.

AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic ...